acor-defa14a_20200828.htm

☐	Preliminary Proxy Statement

☐	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐	Definitive Proxy Statement

☒	Definitive Additional Materials

☐	Soliciting Material under §240.14a-12

☒	No fee required.

☐	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1)

Title of each class of securities to which transaction applies:

(2)

Aggregate number of securities to which transaction applies:

(3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4)

Proposed maximum aggregate value of transaction:

(5)

Total fee paid:

☐	Fee paid previously with preliminary materials.

☐	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1)

Amount Previously Paid:

(2)

Form, Schedule or Registration Statement No.:

(3)

Filing Party:

(4)

Date Filed:

On Friday, August 28, Acorda Therapeutics will reconvene its special meeting of shareholders, which was adjourned on July 31, 2020 in order to provide shareholders more time to vote on Proposal One. Importantly, Proposal One seeks to allow the Company to increase its authorized shares. If approved, Proposal One will give us access to additional shares needed to cover interest payable on, and potential conversion to equity of, our outstanding debt. Without your support on Proposal 1, we could be forced into bankruptcy.

Stockholders have thus far strongly supported Proposal One. The nation’s two leading proxy advisory firms, ISS and Glass Lewis, both recommend their clients vote FOR Proposal One. Additionally, at the July 31st Special Meeting, approximately 80% of the shares that had been voted on Proposal One were voted in its favor. However, the favorable votes on Proposal One were less than the absolute majority of all outstanding shares needed for approval. Thus, your vote is important, no matter how many or how few shares you may own.

If you have not yet voted your shares, please promptly vote FOR by following the easy instructions on the enclosed proxy card or voting instruction form.

If you previously voted against Proposal One, we urge you to reconsider in light of the serious, negative effect that failure to approve Proposal One could have on the value of your investment. Please promptly vote FOR Proposal One by following the easy instructions on the enclosed proxy card or voting instruction form. You have the right to change your vote--only your latest-dated vote will count.

If you have already voted FOR Proposal One, we thank you! There is no need to resubmit your vote.

Our leadership team and board are united in believing that we are on a path to driving value for our shareholders, the patients we serve, and our associates. If you have any questions about Proposal One, please contact Tierney Saccavino at tsaccavino@acorda.com. If you have questions about how to vote your shares, please contact our proxy solicitor, Innisfree M&A Incorporated, toll-free: (877) 717-3929 (from the U.S and Canada) or (412) 232-3651 (from other locations).


420 S AW M ILL R IVER R OAD	P HO NE : ( 914) 347 - 4300	E - M AIL : A CO R DA @ A CO RDA . C OM
A R D SLEY , N Y 10502	F AX : ( 914) 3 47 - 4560	W EBSITE : W W W . A CO RDA . C OM